Literature DB >> 18098322

The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

M Eric Gershwin1, Ian R Mackay.   

Abstract

UNLABELLED: The most difficult issue in autoimmunity remains etiology. Although data exist on effector mechanisms in many autoimmune diseases, the underlying cause or causes are still generically ascribed to genetics and environmental influences. Primary biliary cirrhosis (PBC) is considered a model autoimmune disease because of its signature antimitochondrial autoantibody (AMA), the homogeneity of clinical characteristics, and the specificity of biliary epithelial cell (BEC) pathology. Twenty years ago, we reported the cloning and identification of the E2 component of pyruvate dehydrogenase (PDC-E2) as the immunodominant autoantigen of PBC, allowing for vigorous dissection of T and B lymphocyte responses against PDC-E2 and development of several valid experimental models. There has also been considerable study of the biology of BECs, which has included the unique properties of apoptosis in which there is exposure of PDC-E2 to the effector processes of the immune system. In this review, we present these data in the context of our proposal that the proximal cause of PBC is autoimmunity directed against well-identified mitochondrially located autoantigens in individuals with inherited deficits of immune tolerance. We present these data under the umbrella of convenient truths that support this thesis as well as some inconvenient truths that are not readily accommodated by current theory.
CONCLUSION: We emphasize that the potential initiator of PBC includes inter alia particular environmental xenobiotics; pathogenesis is aided and abetted by genetic weaknesses in mechanisms of immune regulation; and subsequent multilineage immunopathology impacts upon uniquely susceptible BECs to culminate clinically in the chronic autoimmune cholangiolitis of PBC.

Entities:  

Mesh:

Year:  2008        PMID: 18098322     DOI: 10.1002/hep.22042

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  122 in total

1.  Involvement of commensal bacteria may lead to dysregulated inflammatory and autoimmune responses in a mouse model for chronic nonsuppurative destructive cholangitis.

Authors:  Ikuko Haruta; Ken Kikuchi; Minoru Nakamura; Katsuhiko Hirota; Hidehito Kato; Hiroshi Miyakawa; Noriyuki Shibata; Yoichiro Miyake; Etsuko Hashimoto; Keiko Shiratori; Junji Yagi
Journal:  J Clin Immunol       Date:  2012-06-03       Impact factor: 8.317

2.  T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1.

Authors:  Weici Zhang; Yoko Ono; Yoshinori Miyamura; Christopher L Bowlus; M Eric Gershwin; Emanual Maverakis
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

3.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 4.  Infection as a cause of type 1 diabetes?

Authors:  Urs Christen; Christine Bender; Matthias G von Herrath
Journal:  Curr Opin Rheumatol       Date:  2012-07       Impact factor: 5.006

Review 5.  Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature.

Authors:  Nicola Bizzaro; Giovanni Covini; Floriano Rosina; Paolo Muratori; Elio Tonutti; Danilo Villalta; Fiorenza Pesente; Maria Grazia Alessio; Marilina Tampoia; Antonio Antico; Stefan Platzgummer; Brunetta Porcelli; Lucia Terzuoli; Marco Liguori; Danila Bassetti; Ignazio Brusca; Piero L Almasio; Giuseppe Tarantino; Chiara Bonaguri; Paolo Agostinis; Elena Bredi; Renato Tozzoli; Pietro Invernizzi; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

6.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

7.  The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice.

Authors:  Yugo Ando; Guo-Xiang Yang; Masanobu Tsuda; Kazuhito Kawata; Weici Zhang; Takahiko Nakajima; Koichi Tsuneyama; Patrick Leung; Zhe-Xiong Lian; Kazuichi Okazaki; William M Ridgway; Gary L Norman; Aftab A Ansari; Xiao-Song He; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

8.  The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis.

Authors:  Takashi Tomiyama; Guo-Xiang Yang; Ming Zhao; Weici Zhang; Hajime Tanaka; Jing Wang; Patrick Sc Leung; Kazuichi Okazaki; Xiao-Song He; Qianjin Lu; Ross L Coppel; Christopher L Bowlus; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

9.  Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease.

Authors:  Kanji Wakabayashi; Zhe-Xiong Lian; Patrick S C Leung; Yuki Moritoki; Koichi Tsuneyama; Mark J Kurth; Kit S Lam; Katsunori Yoshida; Guo-Xiang Yang; Toshifumi Hibi; Aftab A Ansari; William M Ridgway; Ross L Coppel; Ian R Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

10.  Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFβRII mice.

Authors:  Kazuhito Kawata; Guo-Xiang Yang; Yugo Ando; Hajime Tanaka; Weici Zhang; Yoshimasa Kobayashi; Koichi Tsuneyama; Patrick S C Leung; Zhe-Xiong Lian; William M Ridgway; Aftab A Ansari; Xiao-Song He; M Eric Gershwin
Journal:  Hepatology       Date:  2013-07-24       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.